Literature DB >> 24802766

Seroepidemiology of tetanus in Korean adults and adolescents in 2012.

Hyunwoo Sung1, Mi Jin Jang1, E Young Bae2, Seung Beom Han2, Jong-Hyun Kim2, Jin Han Kang3, Yeon-Joon Park4, Sang Hyuk Ma5.   

Abstract

This seroepidemiologic study was performed to evaluate the immune status against tetanus in Korean adolescents and adults and to provide evidence to develop strategies for tetanus prevention. Between July 2012 and December 2012, serum samples were collected from adults and adolescents 11 years of age and older, and serum anti-tetanus IgG titers were determined using a commercial ELISA kit. Subjects were divided into six age groups: 11-20 years, 21-30 years, 31-40 years, 41-50 years, 51-60 years, and ≥61 years. The mean anti-tetanus IgG titers and tetanus seroprevalence of the age groups were compared. A total of 1193 adults and adolescents were enrolled. Mean anti-tetanus IgG titer and tetanus seroprevalence of all subjects were 1.20 ± 3.58 IU/mL and 56.4%, respectively. The mean anti-tetanus IgG titer decreased with an increase in age (p < 0.001). Tetanus seroprevalence increased from 92.0% in the 11-20 year age group to 95.7% in the 21-30 year age group, and then decreased with a further increase in age (p < 0.001). These results reflected an appropriate Td booster vaccine coverage at 11-12 years of age. However, the tetanus seroprevalence of adults older than 41 years was as low as the levels in previous studies: therefore, adults should be more encouraged to acquire decennial Td booster vaccinations recommended by the National Immunization Program.
Copyright © 2014 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Diphtheria-tetanus vaccine; Epidemiology; Republic of Korea; Tetanus

Mesh:

Substances:

Year:  2014        PMID: 24802766     DOI: 10.1016/j.jiac.2014.03.008

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  6 in total

1.  Seroepidemiology of tetanus in Hangzhou from 2009 to 2018.

Authors:  Yuyang Xu; Yan Liu; Jian Du; Wei Zheng; Shijun Liu; Xuechao Zhang; Xiaoping Zhang; Jun Wang; Xinren Che; Wenwen Gu; Wei Jiang
Journal:  Hum Vaccin Immunother       Date:  2020-05-27       Impact factor: 3.452

Review 2.  Tetanus-diphtheria-acellular pertussis vaccination for adults: an update.

Authors:  Hyo-Jin Lee; Jung-Hyun Choi
Journal:  Clin Exp Vaccine Res       Date:  2017-01-25

3.  Clinical outcomes and healthcare costs of inpatients with tetanus in Korea, 2011-2019.

Authors:  Sook-In Jung; Hyun-Ha Chang; Sohyun Bae; Minsik Go; Yoonjung Kim; Soyoon Hwang; Shin-Woo Kim; Ki Tae Kwon
Journal:  BMC Infect Dis       Date:  2021-03-09       Impact factor: 3.090

4.  Immunogenicity and Safety of a Newly Developed Tetanus-Diphtheria Toxoid (Td) in Healthy Korean Adolescents: a Multi-center, Randomized, Double-blind, Active-Controlled Phase 3 Trial.

Authors:  Ui Yoon Choi; Ki Hwan Kim; Jin Lee; Byung Wook Eun; Hwang Min Kim; Kyung-Yil Lee; Dong Ho Kim; Sang Hyuk Ma; Jina Lee; Jong-Hyun Kim
Journal:  J Korean Med Sci       Date:  2021-12-20       Impact factor: 2.153

5.  Determination of Tetanus Antibody Levels in Trauma Patients Referred To Shahid Beheshti Hospital in Kashan, Iran, 2014.

Authors:  Hasan Afzali; Mohammad Reza Sharif; Shamsaddin Mousavi
Journal:  Arch Trauma Res       Date:  2015-08-24

6.  A Phase III Study to Evaluate the Immunogenicity and Safety of GC1107 (Adult Tetanus Diphtheria Vaccine) in Healthy Adults.

Authors:  Jacob Lee; Jung-Hyun Choi; Seong-Heon Wie; Sun Hee Park; Su-Mi Choi; Mi Suk Lee; Tae Hyong Kim; Hyo-Jin Lee; Jin Han Kang
Journal:  J Korean Med Sci       Date:  2019-01-16       Impact factor: 2.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.